KLI

검색

Ulsan Univ. Repository

Browsing by 저자 : Thomas Powles

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

가 나 다 라 마 바 사 아 자 차 카 타 파 하

또는 첫 단어:

정렬 기준:
정렬:
결과 수
저자 수

전체 결과 10건 중 1-10 번을 표시중입니다.

1 Article Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias ; et al 2023
2 Article Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis Yoshihiko Tomita ; Yoshiaki Yamamoto ; Norihiko Tsuchiya ; et al 2023
3 Article Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium Kosuke Takemura ; Vishal Navani ; Matthew S Ernst ; et al 2023
4 Article Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma 이재련 ; Christof Vulsteke ; Chunzhang Wu ; et al 2021
5 Article Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy Ronald de Wit ; Thomas Powles ; Daniel Castellano ; et al 2022
6 Article Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma Robert J Motzer ; Thomas Powles ; Michael B Atkins ; et al 2022
7 Article Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE) 이재련 ; Alexandra Drakaki ; Andrea Necchi ; et al 2020
8 Article Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles ; Piotr Tomczak ; Se Hoon Park ; et al 2022
9 Article Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma Guru P Sonpavde ; Cora N Sternberg ; Yohann Loriot ; et al 2022
10 Article Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials Joaquim Bellmunt ; Ronald de Wit ; Yves Fradet ; et al 2022

OAK Ulsan Univ. Repository는 국립중앙도서관 OAK Repository 보급사업으로 구축되었습니다.